Center for Single Particle Science and Engineering (SPSE), Institute for Molecular Medicine, Health Sciences, University Southern Denmark, Campusvej 55, Odense DK-5230, Denmark; Clinical Neurosciences Research Laboratory, Health Research Institute of Santiago de Compostela (IDIS), Travesa da Choupana s/n, Santiago de Compostela 15706, Spain.
Department of Nuclear Medicine, Odense University Hospital, Sdr. Boulevard 29, Odense 5000, Denmark.
J Control Release. 2018 Dec 10;291:11-25. doi: 10.1016/j.jconrel.2018.09.027. Epub 2018 Oct 3.
While small molecules can be used in cancer diagnosis there is a need for imageable diagnostic NanoParticles (NPs) that act as surrogates for the therapeutic NPs. Many NPs are composed of hydrophobic materials so the challenge is to formulate hydrophobic imaging agents. To develop individualized medical treatments based on NP, a first step should be the selection of patients who are likely responders to the treatment as judged by imaging tumor accumulation of NPs. This requires NPs with the same size and structure as the subsequent therapeutic NPs but labelled with a long-lived radionuclide. Cobalt isotopes are good candidates for NP labelling since Co has half-life of 17.5 h and positron energy of 570 keV while Co (t 271.6 d) is an isotope suited for preclinical single photon emission tomography (SPECT) to visualize biodistribution and pharmacokinetics of NPs. We used the hydrophobic octaethyl porphyrin (OEP) to chelate cobalt and to encapsulate it inside hydrophobic liquid NPs (LNPs). We hypothesized that at least two additional hydrophobic axial ligands (oleylamine, OA) must be provided to the OEP-Co complex in order to encapsulate and retain Co inside LNP.
The additional hydrophobic chelator OA was indeed needed to obtain a stable octahedral OEP-Co-4OA. Cobalt was actually well-retained inside LNP in the OEP-Co-4OA complex. The method described in the present work for the core-labelling of LNPs with cobalt is now ready for labeling of NPs with Co, or indeed other hexadentate radionuclides of interest for preclinical in vivo PET-imaging and radio-therapeutics.
虽然小分子可用于癌症诊断,但仍需要可成像的诊断性纳米颗粒(NPs)作为治疗性 NPs 的替代品。许多 NPs 由疏水性材料组成,因此挑战在于制定疏水性成像剂。为了基于 NP 制定个体化医疗方案,首先应该选择可能对治疗有反应的患者,这可以通过成像肿瘤中 NP 的积累来判断。这需要与后续治疗性 NPs 具有相同大小和结构但用长半衰期放射性核素标记的 NPs。钴同位素是 NP 标记的良好候选物,因为 Co 的半衰期为 17.5 h,正电子能量为 570 keV,而 Co(t 271.6 d) 是适合临床前单光子发射断层扫描(SPECT)的同位素,用于可视化 NPs 的生物分布和药代动力学。我们使用疏水性八乙基卟啉(OEP)螯合钴并将其封装在疏水性液体 NPs(LNPs)中。我们假设,为了封装和保留 Co 在内的 LNP 中,OEP-Co 络合物中至少需要另外两个疏水性轴向配体(油胺,OA)。
确实需要额外的疏水性螯合剂 OA 才能获得稳定的八面体 OEP-Co-4OA。钴实际上在 OEP-Co-4OA 配合物中很好地保留在 LNP 内。目前在本工作中描述的用钴对 LNPs 进行核心标记的方法现已准备好对 Co 或其他六配位感兴趣的放射性核素进行 NP 标记,用于临床前体内 PET 成像和放射治疗。